

PROVIDER NOTIFICATION OF RETAIL DRUG POLICY CRITERIA CHANGE			
Drug(s) Impacted	CRITERIA CHANGE	EFFECTIVE DATE	Formulary
Fabhalta	For primary immunoglobulin A nephropathy (IgAN) updated urine protein-to-creatinine ratio (UPCR) requirement from 0.8 g/g to 0.5 g/g. Reworded continuation criteria for IgAN to add decreased levels of proteinuria from baseline and decrease in UPCR from baseline as examples of benefit. Also added stabilization of proteinuria, UPCR, or kidney function as additional examples of benefit.	8/10/2026	Essential
Hympavzi	Updated the program to provide coverage in pediatric patients 6 years of age and older and removed requirement for weight $\geq$ 35 kg in alignment with age expansion in the FDA-approved labeling.	8/10/2026	Essential